Top

Published in:

01-03-2022 | Systemic Lupus Erythematosus | News item

Drug safety update: hydroxychloroquine, chloroquine coadministered with macrolide antibiotics

Published in: Reactions Weekly | Issue 1/2022

Excerpt

In a drug safety update, the UK Medicines and Healthcare products Regulatory Agency (MHRA) is warning of the increased risk of cardiovascular events from the coadministration of hydroxychloroquine or chloroquine with macrolide-based antibiotics; the MHRA also reminds consumers and healthcare professionals of the risk of psychiatric disorders from the use of hydroxychloroquine or chloroquine. …

Medicines and Healthcare products Regulatory Agency. Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions. Internet Document : 15 Feb 2022. Available from: URL: https://www.gov.uk/drug-safety-update/hydroxychloroquine-chloroquine-increased-risk-of-cardiovascular-events-when-used-with-macrolide-antibiotics-reminder-of-psychiatric-reactions

Title: Drug safety update: hydroxychloroquine, chloroquine coadministered with macrolide antibiotics
Publication date: 01-03-2022
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
Chloroquin
Macrolide
Macrolide Antibiotic
Erythromycin
Clarithromycin
Azithromycin
Chloroquin
Rheumatoid Arthritis
Sulfasalazine
Hydroxychloroquine
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-11238-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drug safety update: hydroxychloroquine, chloroquine coadministered with macrolide antibiotics

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Hydroxychloroquine

Benzathine benzylpenicillin

Alprazolam/aripiprazole/fluoxetine

Elasomeran

Methylprednisolone/prednisone

Epinephrine